{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:35:05Z","timestamp":1780598105057,"version":"3.54.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.humimm.2024.111152","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T03:32:37Z","timestamp":1728963157000},"page":"111152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect modification between HLA-F and CD56 markers reveals differences in survival for triple-negative breast cancer patients"],"prefix":"10.1016","volume":"85","author":[{"given":"Nanna","family":"Heldager Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Nascimento Melsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scheike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Ole","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances M.","family":"Reznitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bzorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Vibeke","family":"L\u00e6nkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Vauvert F.","family":"Hviid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humimm.2024.111152_b0005","series-title":"Breast tumour. WHO classification of tumours","author":"Ellis","year":"2019"},{"issue":"2","key":"10.1016\/j.humimm.2024.111152_b0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch Obstet. Gynaecol."},{"key":"10.1016\/j.humimm.2024.111152_b0015","doi-asserted-by":"crossref","first-page":"1095839","DOI":"10.3389\/fgene.2022.1095839","article-title":"Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy","volume":"13","author":"Loizides","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.humimm.2024.111152_b0020","article-title":"Breast cancer histopathology in the age of molecular oncology","author":"Kos","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"22","key":"10.1016\/j.humimm.2024.111152_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225694","article-title":"European working group for breast screening, triple-negative breast cancer histological subtypes with a favourable prognosis","volume":"13","author":"Cserni","year":"2021","journal-title":"Cancers (basel)."},{"issue":"7","key":"10.1016\/j.humimm.2024.111152_b0030","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.humimm.2024.111152_b0035","doi-asserted-by":"crossref","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.humimm.2024.111152_b0040","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.humimm.2024.111152_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.910976","article-title":"Immune lymphocyte infiltrate and its prognostic value in triple-negative breast cancer","volume":"12","author":"Huertas-Caro","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.humimm.2024.111152_b0050","doi-asserted-by":"crossref","first-page":"1194020","DOI":"10.3389\/fimmu.2023.1194020","article-title":"The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2024.111152_b0055","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1186\/bcr3148","article-title":"CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer","volume":"14","author":"Liu","year":"2012","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.humimm.2024.111152_b0060","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.humimm.2024.111152_b0065","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-024-03661-8","article-title":"Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis","author":"de Moraes","year":"2024","journal-title":"Clin. Transl. Oncol."},{"issue":"15","key":"10.1016\/j.humimm.2024.111152_b0070","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/0284186X.2012.731520","article-title":"Prognostic impact of FOXP3 expression in triple-negative breast cancer","volume":"52","author":"Lee","year":"2013","journal-title":"Acta Oncol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0080","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-018-0942-x","article-title":"Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population","volume":"20","author":"Schmidt","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.humimm.2024.111152_b0085","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-08-2360","article-title":"Regulatory T cells recruited through CCL22\/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome","volume":"69","author":"Gobert","year":"2009","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.humimm.2024.111152_b0090","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s10585-013-9602-9","article-title":"Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs","volume":"30","author":"Demir","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"issue":"2","key":"10.1016\/j.humimm.2024.111152_b0095","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3089.2010.00571.x","article-title":"Foxp3 regulates human natural CD4+CD25+ regulatory T-cell-mediated suppression of xenogeneic response","volume":"17","author":"Sun","year":"2010","journal-title":"Xenotransplantation"},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/bjc.2012.524","article-title":"Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer","volume":"108","author":"West","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.humimm.2024.111152_b0105","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.humimm.2024.111152_b0110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13058-014-0432-8","article-title":"Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration","volume":"16","author":"Liu","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.humimm.2024.111152_b0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0092-8674(81)90318-4","article-title":"Major histocompatibility antigens: The human (HLA-A,-B,-C) and murine (H-2K, H-2D) class I molecules","volume":"24","author":"Ploegh","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.humimm.2024.111152_b0120","series-title":"Natural killer cells","author":"Abbas","year":"2012"},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/scbi.2001.0404","article-title":"HLA class I antigen abnormalities and immune escape by malignant cells","volume":"12","author":"Seliger","year":"2002","journal-title":"Semin. Cancer Biol."},{"issue":"6669","key":"10.1016\/j.humimm.2024.111152_b0130","first-page":"795","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A","volume":"391","author":"Braud","year":"1998","journal-title":"B and c, Nature."},{"issue":"6","key":"10.1016\/j.humimm.2024.111152_b0135","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.immuni.2017.06.002","article-title":"Human Leukocyte Antigen F Presents Peptides and Regulates Immunity through Interactions with NK Cell Receptors","volume":"46","author":"Dulberger","year":"2017","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.humimm.2024.111152_b0140","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.4049\/jimmunol.1900562","article-title":"Structural and Functional Basis for LILRB Immune Checkpoint Receptor Recognition of HLA-G Isoforms","volume":"203","author":"Kuroki","year":"2019","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.humimm.2024.111152_b0145","first-page":"1433","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.humimm.2024.111152_b0150","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/pin.12343","article-title":"Clinical implication of human leukocyte antigen (HLA)-F expression in breast cancer","volume":"65","author":"Harada","year":"2015","journal-title":"Pathol. Int."},{"key":"10.1016\/j.humimm.2024.111152_b0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.ai.2015.04.001","article-title":"HLA-G: An Immune Checkpoint Molecule","volume":"127","author":"Carosella","year":"2015","journal-title":"Adv. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2024.111152_b0160","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.humimm.2024.111152_b0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/intimm\/dxh194","article-title":"PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells","volume":"17","author":"Iwai","year":"2004","journal-title":"Int. Immunol."},{"key":"10.1016\/j.humimm.2024.111152_b0170","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.2147\/CMAR.S185176","article-title":"The clinical promise of immunotherapy in triple-negative breast cancer","volume":"10","author":"Vikas","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"22","key":"10.1016\/j.humimm.2024.111152_b0175","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10265","key":"10.1016\/j.humimm.2024.111152_b0180","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.humimm.2024.111152_b0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.humimm.2024.111152_b0190","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1349-7006.2006.00317.x","article-title":"Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5","volume":"97","author":"Tsukahara","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.humimm.2024.111152_b0195","doi-asserted-by":"crossref","unstructured":"R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, S. Wienert, G. Van den Eynden, F.L. Baehner, F. Penault-Llorca, E.A. Perez, E.A. Thompson, W.F. Symmans, A.L. Richardson, J. Brock, C. Criscitiello, H. Bailey, M. Ignatiadis, G. Floris, J. Sparano, Z. Kos, T. Nielsen, D.L. Rimm, K.H. Allison, J.S. Reis-Filho, S. Loibl, C. Sotiriou, G. Viale, S. Badve, S. Adams, K. Willard-Gallo, S. Loi, T.W.G. International, The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Ann Oncol. 26 (2) (2015) 259-271.","DOI":"10.1093\/annonc\/mdu450"},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.humimm.2024.111152_b0205","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"Pt 2","key":"10.1016\/j.humimm.2024.111152_b0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00428-022-03276-w","article-title":"Incorporation of TILs in daily breast cancer care: how much evidence can we bear?","volume":"480","author":"Laenkholm","year":"2022","journal-title":"Virchows Arch."},{"issue":"12","key":"10.1016\/j.humimm.2024.111152_b0220","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0344-0338(11)80439-5","article-title":"Prognostic significance of T-cell infiltrates, expression of beta 2-microglobulin and HLA-DR antigens in breast carcinoma","volume":"190","author":"Lucin","year":"1994","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.humimm.2024.111152_b0225","first-page":"817","article-title":"Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas","volume":"3","author":"Menard","year":"1997","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.humimm.2024.111152_b0230","doi-asserted-by":"crossref","first-page":"e0175128","DOI":"10.1371\/journal.pone.0175128","article-title":"Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors","volume":"12","author":"Martinez-Canales","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0235","doi-asserted-by":"crossref","first-page":"20367","DOI":"10.1038\/s41598-022-24890-3","article-title":"Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer","volume":"12","author":"Han","year":"2022","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.humimm.2024.111152_b0240","first-page":"2279","article-title":"Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer","volume":"35","author":"Ishigami","year":"2015","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.humimm.2024.111152_b0245","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jss.2013.04.003","article-title":"Clinical-pathological implication of human leukocyte antigen-F-positive gastric adenocarcinoma","volume":"184","author":"Ishigami","year":"2013","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ijc.27621","article-title":"Alteration of HLA-F and HLA I antigen expression in the tumor is associated with survival in patients with esophageal squamous cell carcinoma","volume":"132","author":"Zhang","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.humimm.2024.111152_b0255","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.lungcan.2011.04.006","article-title":"HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer","volume":"74","author":"Lin","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.humimm.2024.111152_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.600727","article-title":"Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer","volume":"27","author":"Qi","year":"2021","journal-title":"Pathol. Oncol. Res."},{"issue":"12","key":"10.1016\/j.humimm.2024.111152_b0265","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.7150\/thno.43744","article-title":"Discrete functional and mechanistic roles of chromodomain Y-like 2 (CDYL2) transcript variants in breast cancer growth and metastasis","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics."},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0270","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13058-017-0867-9","article-title":"Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours","volume":"19","author":"Shenouda","year":"2017","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.humimm.2024.111152_b0275","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.humimm.2024.111152_b0280","doi-asserted-by":"crossref","first-page":"e2200317","DOI":"10.1200\/PO.22.00317","article-title":"Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis","volume":"7","author":"Loi","year":"2023","journal-title":"JCO Precis. Oncol."},{"issue":"5_Supplement","key":"10.1016\/j.humimm.2024.111152_b0285","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-PD9-02","article-title":"Abstract PD9-02: MHC class I and PD-L1 expression in triple-negative breast cancer subtypes: impact on T-cell infiltration and clinical outcome","volume":"83","author":"Lee","year":"2023","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.humimm.2024.111152_b0290","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-016-3743-x","article-title":"Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer","volume":"156","author":"Matsumoto","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.humimm.2024.111152_b0295","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0632-x","article-title":"Prognostic significance of tumor-infiltrating CD8(+) and FOXP3(+) lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study","volume":"17","author":"Miyashita","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.humimm.2024.111152_b0300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-017-4161-4","article-title":"Higher densities of Foxp3(+) regulatory T cells are associated with better prognosis in triple-negative breast cancer","volume":"163","author":"Yeong","year":"2017","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"10.1016\/j.humimm.2024.111152_b0305","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41416-021-01514-7","article-title":"Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer","volume":"125","author":"Jorgensen","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.humimm.2024.111152_b0310","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1878-0261.12119","article-title":"Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients","volume":"11","author":"Tronik-Le Roux","year":"2017","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.humimm.2024.111152_b0315","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fonc.2018.00361","article-title":"Clinical Significance of Potential Unidentified HLA-G Isoforms Without alpha1 Domain but Containing Intron 4 in Colorectal Cancer Patients","volume":"8","author":"Lin","year":"2018","journal-title":"Front. Oncol."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885924004154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:34:02Z","timestamp":1733880842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885924004154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0198885924004154"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111152","relation":{},"ISSN":["0198-8859"],"issn-type":[{"value":"0198-8859","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect modification between HLA-F and CD56 markers reveals differences in survival for triple-negative breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2024.111152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111152"}}